9 completed, 8 recruiting, 5 not yet recruiting, 1 active not recruiting. 5 Not applicable, 5 Phase 4, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 4, Not yet recruiting 1 |
| Phase 4 | 5 | Recruiting 4, Not yet recruiting 1 |
| Early Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Glucagon-Like Peptide-1 Receptor Agonists: new trials by email Literature Review of Glucagon-Like Peptide-1 Receptor Agonists trials Research Report on Glucagon-Like Peptide-1 Receptor Agonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of GLP-1 Receptor Agonists on Saliva and Oral Health GLP-1 Receptor Agonists - Type 2 Diabetes, Obesity & Overweight | Not yet recruiting | Kırıkkale University | 50 | 2026-10-16 | 2026-09-14 | |
| Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression Structured weight loss program including behavioral support and optional meal re-placement or pharmacotherapy with Glucagon-like peptide-1 receptor agonists (GLP1-RA), Standard Care (in control arm) - Atrial Fibrillation (AF), Obesity & Overweight | Not applicable | Not yet recruiting | Axel Brandes | 480 | 2026-10-01 | 2026-10-05 |
| GLP-1s in Hip and Knee Arthroplasty GLP-1 Receptor Agonists + Behavioral modification, Behavioral + placebo - Arthritis, Obesity & Overweight | Phase 4 | Not yet recruiting | Nova Scotia Health Authority | 100 | 2026-10-01 | 2026-08-10 |
| Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE) GLP-1 Receptor Agonists, SGLT2 inhibitor - Type 2 Diabetes Mellitus, Diabetic Retinopathy (DR) | Not yet recruiting | Thammasat University Hospital | 126 | 2026-09-01 | 2026-08-31 | |
| Comparing Facial Aging Between Identical Twins With 3D Imaging GLP-1 Receptor Agonists - Facial Skin Aging, Facial Volume Loss | Not yet recruiting | Ponsky Facial Aesthetics And Plastic Surgery, Llc | 200 | 2026-08-08 | 2026-08-12 | |
| Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial GLP-1 agonists, Nutrition Counseling - Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Medical College of Wisconsin | 22 | 2026-05-01 | 2026-08-10 |
| Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes GLP-1 Receptor Agonists - Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) | Phase 4 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 60 | 2026-04-01 | 2026-04-30 |
| Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases GLP-1 Receptor Agonists - Diabetes, Obesity & Overweight | Recruiting | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 100 | 2026-02-19 | 2026-07-14 | |
| Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. GLP-1 Receptor Agonists - Short Bowel Syndrome (SBS), Intestinal Failure | Not applicable | Completed | Jinling Hospital, China | 20 | 2026-01-24 | 2026-07-14 |
| Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect) - Liver Cirrhoses, Portal Hypertension Related to Cirrhosis | Phase 4 | Recruiting | The Cleveland Clinic | 70 | 2025-12-17 | 2026-10-22 |
| Transformative Research in Diabetic Nephropathy 2.0 Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA) - Diabetic Nephropathies, Kidney Diseases | Recruiting | University of Pennsylvania | 200 | 2025-11-12 | 2026-03-02 | |
| Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) GLP-1 Receptor Agonists - Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder) | Recruiting | Nemours Children's Clinic | 20 | 2025-09-11 | 2026-09-18 | |
| Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Control (Standard treatment) - Osteoarthritis (OA) of the Knee | Early Phase 1 | Active not recruiting | The University of Hong Kong | 54 | 2025-09-01 | 2026-08-19 |
| Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema GLP-1 Receptor Agonists - Lymphedema | Early Phase 1 | Recruiting | Advanced Reconstructive Surgery Alliance | 110 | 2025-04-09 | 2025-06-10 |
| Antidiabetic Medications and Risk of Cancer Metformin, sulphonylurea, DPP-4 inhibitor - Cancer | Completed | University of Pecs | 74799 | 2025-03-15 | 2026-06-05 | |
| GLP_1 RA Ultrasound Study Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound - Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying | Enrolling by invitation | Children's Hospital Medical Center, Cincinnati | 100 | 2024-07-08 | 2024-11-07 | |
| Impact GLP-1 Agonists Following Bariatric GLP-1 receptor agonist - Morbid Obesity, Metabolic Syndrome | Phase 4 | Recruiting | University of Missouri-Columbia | 150 | 2024-02-01 | 2026-10-21 |
| An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA) - Chronic Kidney Disease, Type 2 Diabetes Mellitus | Completed | Bayer | 50000 | 2022-10-01 | 2024-10-15 | |
| Therapeutic Drug Use for CKD Patients angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker - Chronic Kidney Disease | Unknown | Qianfoshan Hospital | 10000 | 2022-07-01 | 2024-04-03 | |
| Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF Glucagon-like peptide-1 receptor agonists (GLP 1 RA) - Type 2 Diabetes Mellitus (T2DM), Atrial Fibrillation (AF) | Not applicable | Completed | Shanghai Chest Hospital | 174 | 2021-08-01 | 2024-10-28 |
Showing 20 of 26. Sign in to see all of them.
Diabetes Mellitus, Type 2 (12) · Obesity (7) · Overweight (6) · Diabetes Mellitus (3) · Obesity, Morbid (3) · Renal Insufficiency, Chronic (3) · Atrial Fibrillation (2) · Diabetic Nephropathies (2) · Alzheimer Disease (1) · Arthritis (1) · Arthritis, Psoriatic (1) · Cushing Syndrome (1) · Dental Caries (1) · Diabetic Retinopathy (1) · Disease (1)
Canadian Network for Observational Drug Effect Studies, CNODES (3) · Advanced Reconstructive Surgery Alliance (1) · Axel Brandes (1) · Bayer (1) · Centre Hospitalier Universitaire Dijon (1) · Children's Hospital Medical Center, Cincinnati (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Jinling Hospital, China (1) · Kırıkkale University (1) · Medical College of Wisconsin (1) · Nemours Children's Clinic (1) · Nova Scotia Health Authority (1) · Ponsky Facial Aesthetics And Plastic Surgery, Llc (1) · Qianfoshan Hospital (1) · RenJi Hospital (1)
United States (9) · China (6) · Canada (4) · Denmark (2) · Belgium (1) · France (1) · Hong Kong (1) · Hungary (1) · Japan (1) · Netherlands (1) · Spain (1) · Thailand (1) · Turkey (Türkiye) (1)
Pierre Ernst, MD, MSc (3) · Ali Aminian, MD (1) · Andrew Wheeler, MD (1) · Axel Brandes, M.D. (1) · Dr. Diana Ponsky, MD, FACS (1) · Eva Prescott, PhD (1) · Kanokporn Sanpawithayakul, MD, MSc, PhD (1) · Katalin Susztak, MD, PhD (1) · Lawrence Lau, FRCS, PhD (1) · Tao Tao, MD (1) · Xinying Wang, MD (1) · Xu Liu, Dr (1)
PMID 12716821, PMID 16014401, PMID 19259827, PMID 20460434, PMID 24567799, PMID 25685280, PMID 26254961, PMID 26888382, PMID 27007958, PMID 27479930, PMID 31552598, PMID 32497872, PMID 33292149, PMID 33804063, PMID 34317590, PMID 34793438, PMID 37021204, PMID 37397902, PMID 39900263, PMID 41364416